Netherlands-based Life Sciences Partners has collaborated with United States-based Bristol-Myers Squibb.

It was reported yesterday that the collaboration is aimed at finding out European breakthrough technologies and products in immuno-oncology and other areas. Bristol-Myers Squibb has invested an undisclosed amount in LSP 5, the latest LSP fund. It is the first investment by the firm in a European healthcare fund. A representative of Bristol-Myers Squibb will join the LSP 5 advisory board.

Bristol-Myers Squibb senior vice president of business development, Paul Biondi, said, 'Bristol-Myers Squibb is committed to working closely with the venture community to identify and invest in innovative science that has the potential to bring forward transformational medicines to patients with unmet need.'